BridgeBio Oncology slides as it tightens the scope of its KRAS program
BridgeBio Oncology Therapeutics' share price {$BBOT} plummeted by about 24% at market close Wednesday on the back of plans that it is scaling back its pipeline to focus on developing its lead KRAS inhibitor for ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.